Cassava’s Alzheimer’s drug fails in late-stage study

(Reuters) – Cassava Sciences on Monday said its experimental Alzheimer’s disease drug did not meet the main or secondary goals in a late-stage study.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Tasim Zahid)